KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Liabilities (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Total Liabilities for 17 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 13.23% year-over-year to $1.5 billion, compared with a TTM value of $1.5 billion through Dec 2025, up 13.23%, and an annual FY2025 reading of $1.5 billion, up 13.23% over the prior year.
  • Total Liabilities was $1.5 billion for Q4 2025 at Biomarin Pharmaceutical, down from $1.6 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.9 billion in Q4 2023 and bottomed at -$4.9 billion in Q3 2023.
  • Average Total Liabilities over 5 years is $695.8 million, with a median of $1.7 billion recorded in 2021.
  • The sharpest move saw Total Liabilities surged 140.16% in 2022, then plummeted 390.55% in 2023.
  • Year by year, Total Liabilities stood at $1.7 billion in 2021, then rose by 1.89% to $1.8 billion in 2022, then rose by 6.67% to $1.9 billion in 2023, then fell by 29.58% to $1.3 billion in 2024, then grew by 13.23% to $1.5 billion in 2025.
  • Business Quant data shows Total Liabilities for BMRN at $1.5 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.4 billion in Q2 2025.